SEC Comment Letter for Genprex, Inc. (GNPX) (CIK 0001595248) (GNPX) — Jan 2, 2020
Genprex, Inc. (GNPX) (CIK 0001595248)
Date: Jan. 2, 2020 · CIK: 0001595248 · Accession: 0000000000-20-000022
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235733
Letter
January 2, 2020 J. Rodney Varner Chief Executive Officer Genprex, Inc. 1601 Trinity Street, Bldg. B, Suite 3.322 Austin, Texas, 78712 Re:Genprex, Inc. Registration Statement on Form S-1 Filed December 27, 2017 File No. 333-235733 Dear Mr. Varner: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard A. Friedman, Esq.
Show Raw Text
January 2, 2020
J. Rodney Varner
Chief Executive Officer
Genprex, Inc.
1601 Trinity Street, Bldg. B, Suite 3.322
Austin, Texas, 78712
Re:Genprex, Inc.
Registration Statement on Form S-1
Filed December 27, 2017
File No. 333-235733
Dear Mr. Varner:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Richard A. Friedman, Esq.